611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line

NurseWise 24-Hour Crisis Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...

Basic InformationLatest News
ACOG: Shared Decision-Making Key to Breast Cancer ScreeningDrug, Herb Interactions Frequent for Cancer PatientsMany With Advanced Cancer Want Secondary Germline Findings InfoSecondhand Smoke Still Plagues Some Cancer SurvivorsBig Gap in Cancer Deaths Between Rich, Poor CountriesMany Doctors Silent on Cost of Cancer CareFamily Hx, Mutation Position Key Variables in BRCA1/2 Cancer RiskWeight-Loss Program Aids Black Breast Cancer SurvivorsWhen Is Risk Highest for Women With Breast Cancer Gene Mutations?Could Certain Hair Dyes, Relaxers Raise Breast Cancer Risk?Childhood Chemo May Have Lasting Effects on MemoryNovel Biomarkers Identified for Prostate Cancer in Non-BlacksModified Colorectal CA Screening Score Improves Risk PredictionRisk of HPV-Linked Second Cancers Up After Anal Cancer'Couch Potatoes' May Face Higher Risk of Kidney, Bladder CancersHealth Tip: Help Prevent Skin CancerWith Summer Sun Comes Heightened Skin Cancer RiskYoung CA Survivors More Often Have Cost-Related NonadherenceCertain Cancer Diagnoses Up in High-Income Counties in U.S.Liver Cancer the Fastest-Growing Cause of Cancer Deaths in U.S.Is Full Lymph Node Removal Always Needed for Melanoma?More Cancers Caught in Wealthy PeopleNurse-Led Psych Intervention Beneficial in Breast CancerU.S. Liver Cancer Deaths Have Doubled Since 1980s: StudyASCO: Industry Perks Influence Physicians' Choice of Cancer RxASCO: SWOG Trials Have Had Considerable Impact on CancerASCO: CAR T-Cell Therapy Promising in Multiple MyelomaPublicly Funded Cancer Trials Gained Americans 3 Million More YearsCan Drug Company Perks Sway Cancer Docs' Prescriptions?ASCO: Abiraterone Extends Survival in Metastatic Prostate CAASCO: Gene-Targeted Drug Shows Efficacy for Child, Adult CancersGene-Based Therapy May Thwart a Tough Blood CancerGene-Targeted Drugs Fight Advanced Lung CancersCancer Drug Helps Some Kids With Rare Type of LeukemiaDrug Helps Fight Breast Tumors Tied to 'Cancer Genes'Reporting Symptoms Online to Docs Helps Cancer Patients Live LongerDrug Extends Lives of Patients With Advanced Prostate Cancer: StudiesPregnancy Doesn't Raise Odds for Breast Cancer's ReturnExperimental Gene-Targeted Drug Hits Cancer Where It LivesChildhood Cancer Survivors Now Living Healthier LivesConquering One Big Cancer Side Effect: FearDark Skin No Shield From Deadly Skin CancerCertain Breast CA Patients Benefit From Adjuvant CapecitabineDrug Xeloda Prolongs Survival for Some Breast Cancer PatientsHigh Costs for Myeloma Patients Not Getting Low-Income SubsidyDaily Texting Effectively Monitors Rx Adherence, Side EffectsScientists Report Progress on Genetic Test for Anal CancerLocation of Body Fat Can Indicate Obesity-Related Cancer RiskBlood Test for Earlier Detection of Pancreatic Cancer FeasibleSocial Contagion Impacts Imaging Use in Breast Cancer
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

Blood Test May Spot Lung Cancer's Return, Even Before Scans

HealthDay News
by -- Robert Preidt
Updated: Mar 20th 2017

new article illustration

MONDAY, March 20, 2017 (HealthDay News) -- A blood test can detect the return of lung cancer months before CT and PET scans, a new study suggests.

The research included 48 adults with stage 2 or 3 locally advanced non-small cell lung cancer (NSCLC). The patients were aged 31 to 84. All were treated with chemotherapy and radiation.

Blood samples were taken before treatment, during treatment, and at six different times during the two years following treatment. The blood samples were checked for increased levels of circulating tumor cells, the researchers said.

The blood tests were able to detect lung cancer recurrence an average of six months before CT and PET scans, the investigators found.

The study was presented March 16 at a meeting of the American Society for Radiation Oncology, in San Francisco. Research presented at meetings should be viewed as preliminary until published in a peer-reviewed journal.

"The additional lead time afforded by an earlier diagnosis may enable doctors to better tailor alternative and salvage treatments to improve their patients' outcomes and quality of life," said lead author Chimbu Chinniah. He is a research fellow in radiation oncology at the University of Pennsylvania School of Medicine in Philadelphia.

"Earlier detection of recurrence may even translate into an increased likelihood of curing these patients when their tumor burden is lowest and thus more likely to respond to therapy," Chinniah suggested in a society news release.

According to the study's senior author, Dr. Charles Simone II, "The future use of circulating tumor cells as a diagnostic and prognostic tool for localized NSCLC looks promising."

Simone said that imaging tests -- such as CT and PET scans -- will remain "the cornerstone of post-treatment surveillance."

But blood tests could be used together with imaging scans. This combination might be a better way to monitor patients after treatment, he added. Simone is an associate professor of radiation oncology at the University of Maryland School of Medicine, in Baltimore.

More information

The U.S. National Cancer Institute has more on lung cancer.